Abdelrahman Noureldin

Abdelrahman Noureldin

Auto-generated profile, based on publicly available information

Abdelrahman Noureldin

Division of Hematology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

15 October 2024 in American Journal of Hematology
Verified
Journal Article
Open access
AZAli Zidan
Ali Zidan
ASAdham El Sherbini
Adham El Sherbini
ANAbdelrahman Noureldin
Abdelrahman Noureldin
DCDavid K. C. Cooper
David K. C. Cooper
Maha OthmanMaha Othman
Maha Othman
The recent report of the first pig kidney transplant in a living human brings hope to thousands of people with end‐stage kidney failure. The scientific community views this early success with caution as kidney xenotransplantation exhibits many challenges and barriers. One of these is coagulation dysregulation. This includes (i) pig von Willebrand Factor (vWF) interaction with human platelets, which can induce abnormal clotting responses, heightening the risk of graft failure, (ii) the inefficiency of pig thrombomodulin in activating human protein C, which emphasizes the species‐specific variations that aggravate coagulation challenges, and (iii) the development of thrombotic microangiopathy in the pig grafts and the occurrence of systemic consumptive coagulopathy in the recipients. Indeed, coagulation dysregulation largely results from differences in endothelial cell response and incompatibilities between pig and human coagulation–anticoagulation pathways. These barriers can be resolved by modifications to pig vWF and the expression of human thrombomodulin and endothelial protein C receptors in pig cells, serving as strategic interventions to align the coagulation systems of the two species more closely. These coagulation challenges have clinical implications in how they affect graft survival and patient outcome. Genetic engineering of the organ‐source pig and the administration of various drugs have assisted in correcting this coagulation dysregulation. Hence, comprehending and controlling coagulation dysregulation is crucial for progress in xenotransplantation as a viable option for treating patients with terminal kidney disease.

16 May 2025 in The American Journal of Surgery
Verified
Journal Article
Closed access
VIVictoria Ivankovic
Victoria Ivankovic
ANAbdelrahman Noureldin
Abdelrahman Noureldin
CDCeline Dainhi
Celine Dainhi
MFMary Farnand
Mary Farnand
RARebecca C. Auer
Rebecca C. Auer
MDMegan Delisle
Megan Delisle

12 May 2026 in Blood Advances
Verified
Journal Article
Open access
ANAbdelrahman Noureldin
Abdelrahman Noureldin
MCMarc Carrier
Marc Carrier